{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"}],"units":"Participants"}],"title":"Baseline evaluable participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"}],"units":"Participants"}],"title":"Post-baseline evaluable participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"}],"units":"Participants"}],"description":"Presence of ADAs against atezolizumab during the study relative to the presence of ADAs at baseline. The percentage of ADA-positive participants after drug administration were determined for participants exposed to atezolizumab. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.","groups":[{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets) PO, BID along with cobimetinib 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 720 mg (three, 240 mg tablets) PO, BID and vemurafenib matching placebo, PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab 840 mg as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG000","title":"Arm B: Atezo + Cobi + Vem"}],"paramType":"NUMBER","populationDescription":"The ADA-evaluable population included participants who received at least one dose of atezolizumab and had ≥ 1 post-baseline ADA result. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-infusion Day 1 of Cycles 1-4 (1 Cycle=28 days); at Atezolizumab discontinuation (approximately up to 33 months)","title":"Percentage of Participants Positive for Anti-drug Antibodies (ADA) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}